Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.79 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30541869 | 0.88 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL30541868 | 0.88 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL28007018 | 0.88 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL28136625 | 0.88 | EPHX2 (1.00) | EPHX2FAAHCNR1 | |
| SCHEMBL934606 | 0.88 | EPHX2 (0.90) | EPHX2FAAHALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30104666 | 0.86 | ALDH1A1 (0.68) | EPHX2ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL8245692 | 0.86 | ALDH1A1 (0.68) | EPHX2ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL3749784 | 0.85 | MEN1 (0.64) | EPHX2MEN1KMT2A | |
| SCHEMBL19002581 | 0.85 | EPHX2 (0.80) | EPHX2FAAHALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7363832 | 0.84 | EPHX2 (0.74) | EPHX2FAAHALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023215314-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3164127-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS, LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003980-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | EPHX2 2043/4885FAAH 3559/4885ALDH1A1 760/4885 |
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | ITGAM, ITGA2, ADGRF1 | EPHX2 1161/4885FAAH 2428/4885ALDH1A1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.